💨 Abstract

A clinical trial found that gantenerumab, an experimental drug, reduced amyloid plaque buildup in the brains of people with early-onset Alzheimer's, slowing cognitive decline. The drug works by signaling the immune system to clear plaques, potentially slowing Alzheimer's progression. However, it has risks, including amyloid-related imaging abnormalities, and its cost could limit access if approved.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖